Phaseline

Companies › SynDevRx

SynDevRx: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Evexomostat (SDX-7320)
MetAP2 inhibitor
METAP2Phase 1HR+/HER2-negative Breast CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05455619Evexomostat (SDX-7320)Phase 1HR+/HER2-negative Breast CancerOncologyDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

METAP2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.